1. Home
  2. STTK vs JLS Comparison

STTK vs JLS Comparison

Compare STTK & JLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

HOLD

Current Price

$3.05

Market Cap

119.0M

Sector

Health Care

ML Signal

HOLD

Logo Nuveen Mortgage and Income Fund

JLS

Nuveen Mortgage and Income Fund

HOLD

Current Price

$18.34

Market Cap

103.4M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
STTK
JLS
Founded
2016
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
119.0M
103.4M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
STTK
JLS
Price
$3.05
$18.34
Analyst Decision
Buy
Analyst Count
5
0
Target Price
$4.00
N/A
AVG Volume (30 Days)
392.9K
26.6K
Earning Date
11-06-2025
01-01-0001
Dividend Yield
N/A
9.33%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,000,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.69
$15.48
52 Week High
$3.38
$17.97

Technical Indicators

Market Signals
Indicator
STTK
JLS
Relative Strength Index (RSI) 67.21 38.95
Support Level $2.82 $18.15
Resistance Level $3.30 $18.51
Average True Range (ATR) 0.24 0.22
MACD -0.00 -0.01
Stochastic Oscillator 74.76 25.88

Price Performance

Historical Comparison
STTK
JLS

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

About JLS Nuveen Mortgage and Income Fund

Nuveen Mortgage And Income Fund is a diversified, closed-end management investment company. The fund invests at least fifty percent of its Managed Assets in MBS, including residential MBS and commercial MBS, and up to fifty percent in non-mortgage related ABS. Its investment objective to generate high current income through opportunistic investments in securitized credit.

Share on Social Networks: